<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639128</url>
  </required_header>
  <id_info>
    <org_study_id>1488728</org_study_id>
    <nct_id>NCT04639128</nct_id>
  </id_info>
  <brief_title>Adductor Canal Catheter Effectiveness and Safety Study</brief_title>
  <acronym>ACCESS</acronym>
  <official_title>An Open-Label Randomized Noninferiority Clinical Trial of the Adductor Canal Catheter for Pain Control Post-Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRIMARY OBJECTIVE: Compare the effect of usual care with an adductor canal catheter (ACC)&#xD;
      containing ropivacaine to the effect of usual care without an ACC on the&#xD;
      second-postoperative-day pain levels among patients undergoing elective primary unilateral&#xD;
      total knee arthroplasty (TKA)&#xD;
&#xD;
      SECONDARY OBJECTIVES: Among a sample of patients undergoing elective primary unilateral TKA&#xD;
      who receive peri-articular anesthetic injections:&#xD;
&#xD;
        1. To compare the overall two-week levels of postoperative pain between those participants&#xD;
           randomized to ACCs containing ropivacaine and those participants randomized to usual&#xD;
           care without an ACC&#xD;
&#xD;
        2. To compare the use of opioid medications (in mean total morphine milligram equivalents)&#xD;
           between those participants randomized to ACCs containing ropivacaine and those&#xD;
           participants randomized to usual care without an ACC over the two-week postoperative&#xD;
           period&#xD;
&#xD;
        3. To describe the incidence of complications related to ACC placement including infection,&#xD;
           displacement, ACC-related clinic or emergency department (ED) visits&#xD;
&#xD;
        4. To conduct exploratory analyses to identify candidate predictors of differential&#xD;
           response to the ACC&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DESIGN: Randomized, open-label, two-arm, parallel-comparison noninferiority trial&#xD;
&#xD;
      POPULATION: Adults aged &gt;18 years intending to undergo elective primary unilateral TKA at the&#xD;
      Kaiser Permanente Northern California, San Leandro Medical Center&#xD;
&#xD;
      INTERVENTION: Participants will be randomized to one of two treatment arms:&#xD;
&#xD;
        1. Adductor canal catheter placement in the pre-operative area immediately prior to TKA&#xD;
           surgery OR&#xD;
&#xD;
        2. No adductor canal catheter placement&#xD;
&#xD;
      DURATION: The intervention phase will occur between randomization and three days&#xD;
      postoperatively (or until the ACC is removed by the participant or the ACC falls out&#xD;
      spontaneously among ACC-randomized participants); the primary outcome will be measured on&#xD;
      postoperative day 2, secondary pain and medication outcomes will be collected for two weeks&#xD;
      postoperatively and the electronic medical record (EMR) will be examined for evidence of&#xD;
      adverse events at 3 months postoperatively&#xD;
&#xD;
      SAMPLE SIZE: 118 participants randomized using balanced allocation to the two study arms&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Numerical Rating Scale</measure>
    <time_frame>Second postoperative day</time_frame>
    <description>Ordinal 0-to-10 point scale of pain severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcomes Score (KOOS) Jr</measure>
    <time_frame>14th postoperative day</time_frame>
    <description>Multidimensional instrument for assessing pain, symptoms, activities of daily living, recreation functioning, and knee-related quality of life; this is an ordinal scale, scored on a 1-to-28 scale with higher numbers indicating more severe symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Total Knee Replacement Surgery</condition>
  <arm_group>
    <arm_group_label>No-Device</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No placement of an adductor canal catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement of an adductor canal catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Adductor Canal Catheter</intervention_name>
    <description>The adductor canal catheter is a medical device that consists of a tunneled catheter connected to an analgesic solution-containing reservoir that slowly infuses the anesthetic over the first 2-3 postoperative days</description>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Intending to undergo elective primary unilateral TKA at the KPNC San Leandro Medical&#xD;
             Center&#xD;
&#xD;
          -  Patient ambulates independently&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient declines use of ACC&#xD;
&#xD;
          -  Surgeon decides that an ACC will not be placed for any reason&#xD;
&#xD;
          -  Known hypersensitivity to ropivacaine or any alternative anesthetic for ACC use&#xD;
&#xD;
          -  Hypersensitivity or inability to tolerate peri-articular injections of clonidine,&#xD;
             epinephrine, bupivacaine and ketorolac&#xD;
&#xD;
          -  Any evidence of substance-use disorder in past year&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Failure to complete all baseline study instruments prior to surgery&#xD;
&#xD;
          -  Requires secondary procedure at time of TKA (e.g., removal of hardware)&#xD;
&#xD;
          -  Not intending to use spinal anesthesia for TKA procedure&#xD;
&#xD;
          -  Actively enrolled in KPNC chronic-pain program&#xD;
&#xD;
          -  Having been prescribed long-acting opioid (e.g., Oxycontin, MS Contin) within 90 days&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Inability to tolerate any oral NSAID or acetaminophen or any short-acting opioid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Hinman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Avins, MD, MPH</last_name>
    <phone>510 891 3596</phone>
    <email>andy.l.avins@kp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaiser Permanente San Leandro</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94577</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andy Avins, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Song MH, Kim BH, Ahn SJ, Yoo SH, Kang SW, Kim YJ, Kim DH. Peri-articular injections of local anaesthesia can replace patient-controlled analgesia after total knee arthroplasty: a randomised controlled study. Int Orthop. 2016 Feb;40(2):295-9. doi: 10.1007/s00264-015-2940-2. Epub 2015 Jul 31.</citation>
    <PMID>26227922</PMID>
  </reference>
  <reference>
    <citation>Manickam B, Perlas A, Duggan E, Brull R, Chan VW, Ramlogan R. Feasibility and efficacy of ultrasound-guided block of the saphenous nerve in the adductor canal. Reg Anesth Pain Med. 2009 Nov-Dec;34(6):578-80.</citation>
    <PMID>19916251</PMID>
  </reference>
  <reference>
    <citation>Kim DH, Lin Y, Goytizolo EA, Kahn RL, Maalouf DB, Manohar A, Patt ML, Goon AK, Lee YY, Ma Y, Yadeau JT. Adductor canal block versus femoral nerve block for total knee arthroplasty: a prospective, randomized, controlled trial. Anesthesiology. 2014 Mar;120(3):540-50. doi: 10.1097/ALN.0000000000000119.</citation>
    <PMID>24401769</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>analgesia</keyword>
  <keyword>surgery</keyword>
  <keyword>device</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Consideration for sharing patient-level data will be made on case-by-case basis via contact with the study PI</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 31, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT04639128/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT04639128/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

